Sanofi plans to invest $2 billion to expand bio pharmaceutical production capacity and introduce talents

Source: drug cube 2017-06-16 evaluatepharma data shows that 70% of the top 100 drugs in global sales before 2010 are small molecule drugs By 2020, this proportion will drop to 50%, and biological drugs will become the mainstream drugs in the market In this trend, pharmaceutical companies attach great importance to the future of biopharmaceutics Roche announced in February that it plans to expand the capacity of biological drugs and reduce the capacity of some small molecule drugs Although Roche did not disclose the investment plan of the biopharmaceutical plant, the industry believed it would be the largest Roche's current biopharmaceutical plants are located in San Francisco, oshenside, wacaville, California, Hillsborough, Oregon and Singapore, and its Japanese subsidiary Chugai has 49000l of capacity in Tokyo Even so, Roche plans to invest more in biopharmaceutics On June 13, Philippe luscan, executive vice president of Sanofi's global industrial affairs, told Reuters that Sanofi will invest 600 million euros (about 673 million US dollars) annually in the field of biological drugs in the next two to three years The accumulated fund of 2 billion US dollars is mainly used to expand the company's biopharmaceutical engineering capacity and expand the talent team in the United States, Germany and France Nicolas kressmann, a spokesman for Sanofi, said: this fund is part of Sanofi's 1 billion euro annual industrial investment plan, and the remaining funds will be used for the production capacity construction of small molecule drugs, which is consistent with the previous investment plans But it was also early this year that Sanofi and Lonza announced that they would invest 270 million euros to build a large factory in Switzerland to produce McAbs The new plant plans to recruit 200 employees, complete in 2019 and put into operation in 2020 "In 2012, 43% of our product pipelines were biopharmaceuticals, and in 2016 and 2020, that figure will reach 60% or more," said luscan Sanofi has invested 3.3 billion euros in biopharmaceutical industry in the past five years and 4.7 billion euros in biopharmaceutical industry The company attaches great importance to this field "In order to improve the R & D and production capacity of McAbs, Sanofi has chosen to cooperate with regeneron and Berlin Ingelheim, the first-class CMO service provider in Germany In March 2017, the FDA approved the new specific dermatitis drug dupixent (dupilumab) of Sanofi / regeneron Dupilumab belongs to anti IL-4R α mAb, which can inhibit the immune response mediated by IL-4R The annual treatment price is $37 thousand In May 2017, the FDA approved the new rheumatoid arthritis drug kevzara (sarilumab) of Sanofi, with the sales peak expected to reach US $5 billion.